Valion Bio, Inc. - Common stock (VBIO)

0.1280
-0.0326 (-20.30%)
NASDAQ· Last Trade: Aug 19th, 12:49 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Kartoon Studios (NYSE: TOON) Enters Next Growth Phase; Reports Q2 Revenue of $5.82M, EPS of $0.38 and $40.5M Cash Position – Plus More in Focus
Aug. 14, 2026 — Kartoon Studios, Inc. (NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.
Via AB Newswire · August 14, 2026
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement
By Valion Bio, Inc. · Via ACCESS Newswire · August 13, 2026
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall
By Valion Bio, Inc. · Via ACCESS Newswire · August 12, 2026